Market Research Report: Global PPARδ (PPAR-Delta) Modulators Market
Report Overview
This report provides a strategic analysis of the global market for Peroxisome Proliferator-Activated Receptor Delta (PPARδ) modulators, covering its current developmental status, forecasted growth, competitive landscape, and key insights for the period 2025 to 2036. The market encompasses a pipeline of investigational small-molecule agonists and antagonists targeting PPARδ, a nuclear receptor involved in lipid metabolism, energy homeostasis, and inflammation, for the treatment of metabolic, inflammatory, and fibrotic diseases.
Executive Summary
The global PPARδ Modulators market is in a pivotal R&D and early clinical phase, with a projected pipeline valuation of USD XX million in 2025. It is anticipated to reach USD YY million by 2036, contingent upon successful late-stage clinical outcomes and first regulatory approvals. This high-risk, high-reward market is driven by the significant unmet need in diseases like metabolic dysfunction-associated steatohepatitis (MASH), primary biliary cholangitis (PBC), and rare metabolic disorders, alongside a deeper understanding of PPARδ biology.
Market Segmentation Analysis
1. By Drug Type (Mechanism of Action):
-
Selective PPARδ Agonists: Designed to activate the receptor, promoting fatty acid oxidation, improving insulin sensitivity, and exerting anti-inflammatory effects. The dominant modality in development (e.g., seladelpar, elafibranor).
-
Dual/Tri-PPAR Agonists: Pan-agonists or dual agonists (e.g., PPARα/δ) aiming for synergistic benefits across multiple metabolic pathways.
-
PPARδ Modulators with Novel MoAs: Including selective PPARδ modulators (SPPARδMs) designed for tissue-specific effects and improved safety profiles.
2. By Therapeutic Application (Indication):
-
Metabolic & Liver Diseases (Primary Focus):
-
Metabolic Dysfunction-Associated Steatohepatitis (MASH): The largest potential market.
-
Primary Biliary Cholangitis (PBC): An established target with late-stage candidates.
-
Other Cholestatic & Fibrotic Liver Diseases.
-
-
Metabolic & Cardiovascular Disorders: Dyslipidemia, Type 2 Diabetes, and cardiovascular risk reduction.
-
Musculoskeletal & Rare Diseases: Ducheme Muscular Dystrophy (DMD), fibrodysplasia ossificans progressiva (FOP).
-
Inflammatory & Autoimmune Conditions: Ulcerative colitis, psoriasis.
3. By Development Phase:
-
Preclinical/Discovery
-
Phase I Clinical Trials (Safety & Pharmacology)
-
Phase II Clinical Trials (Proof-of-Concept; most active segment)
-
Phase III Clinical Trials & Regulatory Review (Future pivotal segment)
-
Post-Marketing (Commercial)
Regional Analysis
-
North America: The leading R&D and future commercial market, spearheaded by the U.S. High concentration of biotech innovation, favorable FDA regulatory pathways (Fast Track, Breakthrough Therapy), and significant venture capital funding.
-
Europe: A major hub for clinical research and development, with strong academic centers and pharmaceutical activity in France, the UK, and Germany. The EMA provides a key regulatory pathway.
-
Asia-Pacific: An increasingly important region for patient recruitment in global trials and a future high-growth market. Japan and China have active domestic developers (e.g., Chipscreen Biosciences) and large patient populations for metabolic diseases.
-
Rest of the World: Participation in multi-regional clinical trials is growing, but commercial markets will follow initial approvals in the U.S., EU, and Japan.
Competitive Landscape & Key Players
The landscape is defined by innovative biotechnology companies, often with partnerships from larger pharmaceutical firms.
-
CymaBay Therapeutics, Inc. (Seladelpar - for PBC and MASH)
-
Genfit SA (Elafibranor - a PPARα/δ agonist for MASH)
-
Inventiva (Lanifibranor - a pan-PPAR agonist for MASH)
-
Ipsen (via acquisition of incomplete assets; active in metabolic diseases)
-
Mitsubishi Tanabe Pharma (through partnerships/in-licensing)
-
Chipscreen Biosciences Ltd (CS-038 and other candidates)
-
Mitobridge Inc. (a subsidiary of Astellas Pharma, focusing on mitochondrial metabolism)
-
T3D Therapeutics, Inc. (T3D-959 for Alzheimer's disease)
-
Other Notable: Connexios Life Sciences, Nippon Chemiphar, Senju Pharmaceutical, NeuroBo Pharmaceuticals.
Strategic Analysis Frameworks
Porter’s Five Forces Analysis
-
Competitive Rivalry: Moderate to High (in R&D phase). Competition is intense to achieve clinical success first in high-value indications like MASH. Rivalry is based on compound differentiation (selectivity, efficacy, safety), speed of development, and strength of clinical data.
-
Bargaining Power of Suppliers: Low to Moderate. Suppliers include CROs and CDMOs, which are specialized but numerous. Unique chemical scaffolds or formulation technologies can increase supplier power.
-
Bargaining Power of Buyers: Potentially Very High (Future). Upon approval, buyers (payers, health systems) will compare efficacy, safety, and cost against other emerging MASH/PBC therapies (e.g., FXR agonists, THRβ agonists) in a potentially crowded market.
-
Threat of New Entrants: Moderate. High scientific and capital barriers exist, but the significant market opportunity in MASH and other metabolic diseases continues to attract new biotech entrants and R&D investments from large pharma.
-
Threat of Substitutes: Very High. Direct competition from other drug classes targeting the same diseases: FXR agonists (obeticholic acid), THRβ agonists (resmetirom), FGF21 analogues, GLP-1 receptor agonists, and others. PPARδ modulators must demonstrate a differentiated benefit-risk profile.
SWOT Analysis
-
Strengths: Targets fundamental pathways in metabolism and inflammation; potential for disease-modifying effects in MASH/fibrosis; oral administration preferred for chronic diseases.
-
Weaknesses: Historical safety concerns with earlier PPAR agonists (cardiovascular, carcinogenicity); unproven long-term clinical efficacy and safety for novel modulators; complex biology with potential pleiotropic effects.
-
Opportunities: Massive unmet need in MASH with no globally approved pharmacotherapy; potential for combination therapies with other mechanisms; expansion into rare muscular and metabolic disorders.
-
Threats: Clinical trial failures leading to pipeline attrition (high risk); stringent regulatory requirements for demonstrating histological improvement in MASH; dominance of other drug classes reaching market first.
Trend Analysis
-
Focus on MASH as the Primary Indication: The majority of recent and planned clinical trials for PPARδ agonists are in MASH, representing the largest commercial opportunity.
-
Precision Targeting & Improved Safety: Development of SPPARδMs and next-generation agonists designed to minimize off-target effects and improve the therapeutic window compared to older PPAR drugs.
-
Biomarker-Driven Development: Use of non-invasive biomarkers (e.g., MRI-PDFF, ELF score, PRO-C3) to monitor treatment response and streamline clinical trials.
-
Exploration of Muscular & Neurological Benefits: Leveraging PPARδ's role in muscle fiber type switching and mitochondrial function for diseases like DMD and Alzheimer's.
-
Strategic Partnerships & M&A: Larger pharmaceutical companies actively seeking to in-license or acquire promising PPARδ assets to bolster their metabolic disease pipelines.
Market Drivers & Challenges
-
Drivers:
-
Global epidemic of obesity, diabetes, and MASH, creating a vast unmet medical need.
-
Advancing understanding of PPARδ's role in regulating metabolism, inflammation, and fibrosis.
-
Significant investment from biotech and pharma in the NASH/MASH therapeutic area.
-
Favorable regulatory designations (Breakthrough Therapy, Fast Track) accelerating development.
-
-
Challenges:
-
Demonstrating Histological Efficacy: High bar for MASH approval requires showing improvement in liver fibrosis without worsening of steatohepatitis.
-
Overcoming Historical Safety Perceptions: Regulators and clinicians are cautious due to past issues with PPARγ agonists (thiazolidinediones).
-
High Development Costs & Attrition Risk: Long, large, and expensive Phase 3 trials in MASH with a high failure rate.
-
Future Market Access & Reimbursement: Must prove cost-effectiveness in competitive landscape.
-
Value Chain Analysis
-
Target Discovery & Validation: Academic and early-stage biotech research elucidating PPARδ's role in disease pathophysiology.
-
Drug Discovery & Optimization: High-throughput screening, medicinal chemistry, and preclinical studies to identify selective, potent, and safe lead candidates.
-
Clinical Development: Phased clinical trials to establish safety, pharmacokinetics, pharmacodynamics, and ultimately efficacy in the target population.
-
Regulatory Affairs & Approval: Navigating complex interactions with FDA, EMA, etc., including advisory committees for novel endpoints (liver histology).
-
Commercial Manufacturing & Supply: Scaling up GMP synthesis of the active pharmaceutical ingredient (API) and formulation.
-
Commercialization & Market Access: Launch, pricing negotiations, securing reimbursement, and marketing to specialist physicians (hepatologists, endocrinologists).
-
Post-Marketing Studies & Lifecycle Management: Phase IV studies and exploration of additional indications.
Quick Recommendations for Stakeholders
-
For Biotechnology Companies (Developers): Prioritize rigorous clinical trial design with clear, regulatory-agreed endpoints, especially for MASH. Invest early in understanding the safety profile to differentiate from older PPAR drugs. Seek strategic partnerships with larger pharma for late-stage development, commercialization, and funding.
-
For Large Pharmaceutical Companies: Actively scout for and in-license promising PPARδ assets with clean safety data and strong Phase 2 proof-of-concept. Integrate these candidates into combination therapy strategies with other metabolic assets (FXR, GLP-1 agonists).
-
For Investors: Conduct deep due diligence on the specific compound's safety data, clinical trial design, and management team. Focus on companies with candidates that have demonstrated a clear efficacy signal on key endpoints (e.g., liver fat reduction, fibrosis improvement) and a manageable safety profile in Phase 2. Diversify across the broader MASH/ metabolic disease therapeutic space.
-
For Research Institutions: Continue fundamental research into tissue-specific functions of PPARδ and its coregulators. Collaborate with industry on translational studies to identify predictive biomarkers of response and better understand mechanisms of action.
-
For Regulatory Agencies: Provide clear guidance on development pathways for MASH therapies, including acceptable surrogate endpoints and combination trial designs. Engage early with sponsors to ensure trial designs are adequate to demonstrate a positive benefit-risk profile for this new class.
Table of Contents
Global Peroxisome Proliferator Activated Receptor Delta Market Research Report 2026
1 Industry Overview of Peroxisome Proliferator Activated Receptor Delta
1.1 Definition and Specifications of Peroxisome Proliferator Activated Receptor Delta
1.1.1 Definition of Peroxisome Proliferator Activated Receptor Delta
1.1.2 Specifications of Peroxisome Proliferator Activated Receptor Delta
1.2 Classification of Peroxisome Proliferator Activated Receptor Delta
1.2.1 MTB-2
1.2.2 HPP-593
1.2.3 CNX-013B2
1.2.4 CS-038
1.2.5 MA-0204
1.2.6 Others
1.3 Applications of Peroxisome Proliferator Activated Receptor Delta
1.3.1 Bone Disorders
1.3.2 Colitis
1.3.3 Obesity
1.3.4 Osteoporosis
1.3.5 Others
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 Europe
1.4.3 China
1.4.4 Japan
1.4.5 Southeast Asia
1.4.6 India
2 Manufacturing Cost Structure Analysis of Peroxisome Proliferator Activated Receptor Delta
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Peroxisome Proliferator Activated Receptor Delta
2.3 Manufacturing Process Analysis of Peroxisome Proliferator Activated Receptor Delta
2.4 Industry Chain Structure of Peroxisome Proliferator Activated Receptor Delta
3 Technical Data and Manufacturing Plants Analysis of Peroxisome Proliferator Activated Receptor Delta
3.1 Capacity and Commercial Production Date of Global Peroxisome Proliferator Activated Receptor Delta Major Manufacturers
3.2 Manufacturing Plants Distribution of Global Peroxisome Proliferator Activated Receptor Delta Major Manufacturers
3.3 R&D Status and Technology Source of Global Peroxisome Proliferator Activated Receptor Delta Major Manufacturers
3.4 Raw Materials Sources Analysis of Global Peroxisome Proliferator Activated Receptor Delta Major Manufacturers
4 Global Peroxisome Proliferator Activated Receptor Delta Overall Market Overview
4.1 E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 E Global Peroxisome Proliferator Activated Receptor Delta Capacity and Growth Rate Analysis
4.2.2 Peroxisome Proliferator Activated Receptor Delta Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 E Global Peroxisome Proliferator Activated Receptor Delta Sales and Growth Rate Analysis
4.3.2 Peroxisome Proliferator Activated Receptor Delta Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 E Global Peroxisome Proliferator Activated Receptor Delta Sales Price
4.4.2 Peroxisome Proliferator Activated Receptor Delta Sales Price Analysis (Company Segment)
5 Peroxisome Proliferator Activated Receptor Delta Regional Market Analysis
5.1 North America Peroxisome Proliferator Activated Receptor Delta Market Analysis
5.1.1 North America Peroxisome Proliferator Activated Receptor Delta Market Overview
5.1.2 North America E Peroxisome Proliferator Activated Receptor Delta Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America E Peroxisome Proliferator Activated Receptor Delta Sales Price Analysis
5.1.4 North America Peroxisome Proliferator Activated Receptor Delta Market Share Analysis
5.2 Europe Peroxisome Proliferator Activated Receptor Delta Market Analysis
5.2.1 Europe Peroxisome Proliferator Activated Receptor Delta Market Overview
5.2.2 Europe E Peroxisome Proliferator Activated Receptor Delta Local Supply, Import, Export, Local Consumption Analysis
5.2.3 Europe E Peroxisome Proliferator Activated Receptor Delta Sales Price Analysis
5.2.4 Europe Peroxisome Proliferator Activated Receptor Delta Market Share Analysis
5.3 China Peroxisome Proliferator Activated Receptor Delta Market Analysis
5.3.1 China Peroxisome Proliferator Activated Receptor Delta Market Overview
5.3.2 China E Peroxisome Proliferator Activated Receptor Delta Local Supply, Import, Export, Local Consumption Analysis
5.3.3 China E Peroxisome Proliferator Activated Receptor Delta Sales Price Analysis
5.3.4 China Peroxisome Proliferator Activated Receptor Delta Market Share Analysis
5.4 Japan Peroxisome Proliferator Activated Receptor Delta Market Analysis
5.4.1 Japan Peroxisome Proliferator Activated Receptor Delta Market Overview
5.4.2 Japan E Peroxisome Proliferator Activated Receptor Delta Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Japan E Peroxisome Proliferator Activated Receptor Delta Sales Price Analysis
5.4.4 Japan Peroxisome Proliferator Activated Receptor Delta Market Share Analysis
5.5 Southeast Asia Peroxisome Proliferator Activated Receptor Delta Market Analysis
5.5.1 Southeast Asia Peroxisome Proliferator Activated Receptor Delta Market Overview
5.5.2 Southeast Asia E Peroxisome Proliferator Activated Receptor Delta Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Southeast Asia E Peroxisome Proliferator Activated Receptor Delta Sales Price Analysis
5.5.4 Southeast Asia Peroxisome Proliferator Activated Receptor Delta Market Share Analysis
5.6 India Peroxisome Proliferator Activated Receptor Delta Market Analysis
5.6.1 India Peroxisome Proliferator Activated Receptor Delta Market Overview
5.6.2 India E Peroxisome Proliferator Activated Receptor Delta Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India E Peroxisome Proliferator Activated Receptor Delta Sales Price Analysis
5.6.4 India Peroxisome Proliferator Activated Receptor Delta Market Share Analysis
6 Global E Peroxisome Proliferator Activated Receptor Delta Segment Market Analysis (by Type)
6.1 Global E Peroxisome Proliferator Activated Receptor Delta Sales by Type
6.2 Different Types of Peroxisome Proliferator Activated Receptor Delta Product Interview Price Analysis
6.3 Different Types of Peroxisome Proliferator Activated Receptor Delta Product Driving Factors Analysis
6.3.1 MTB-2 Growth Driving Factor Analysis
6.3.2 HPP-593 Growth Driving Factor Analysis
6.3.3 CNX-013B2 Growth Driving Factor Analysis
6.3.4 CS-038 Growth Driving Factor Analysis
6.3.5 MA-0204 Growth Driving Factor Analysis
6.3.6 Others Growth Driving Factor Analysis
7 Global E Peroxisome Proliferator Activated Receptor Delta Segment Market Analysis (by Application)
7.1 Global E Peroxisome Proliferator Activated Receptor Delta Consumption by Application
7.2 Different Application of Peroxisome Proliferator Activated Receptor Delta Product Interview Price Analysis
7.3 Different Application of Peroxisome Proliferator Activated Receptor Delta Product Driving Factors Analysis
7.3.1 Bone Disorders of Peroxisome Proliferator Activated Receptor Delta Growth Driving Factor Analysis
7.3.2 Colitis of Peroxisome Proliferator Activated Receptor Delta Growth Driving Factor Analysis
7.3.3 Obesity of Peroxisome Proliferator Activated Receptor Delta Growth Driving Factor Analysis
7.3.4 Osteoporosis of Peroxisome Proliferator Activated Receptor Delta Growth Driving Factor Analysis
7.3.5 Others of Peroxisome Proliferator Activated Receptor Delta Growth Driving Factor Analysis
8 Major Manufacturers Analysis of Peroxisome Proliferator Activated Receptor Delta
8.1 Chipscreen Biosciences Ltd
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 Chipscreen Biosciences Ltd Peroxisome Proliferator Activated Receptor Delta Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Chipscreen Biosciences Ltd Peroxisome Proliferator Activated Receptor Delta Business Region Distribution Analysis
8.2 Connexios Life Sciences Pvt Ltd
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Connexios Life Sciences Pvt Ltd Peroxisome Proliferator Activated Receptor Delta Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Connexios Life Sciences Pvt Ltd Peroxisome Proliferator Activated Receptor Delta Business Region Distribution Analysis
8.3 CymaBay Therapeutics Inc
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 CymaBay Therapeutics Inc Peroxisome Proliferator Activated Receptor Delta Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 CymaBay Therapeutics Inc Peroxisome Proliferator Activated Receptor Delta Business Region Distribution Analysis
8.4 Genfit SA
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 Genfit SA Peroxisome Proliferator Activated Receptor Delta Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Genfit SA Peroxisome Proliferator Activated Receptor Delta Business Region Distribution Analysis
8.5 Inventiva
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 Inventiva Peroxisome Proliferator Activated Receptor Delta Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Inventiva Peroxisome Proliferator Activated Receptor Delta Business Region Distribution Analysis
8.6 Mitobridge Inc
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Product A
8.6.2.2 Product B
8.6.3 Mitobridge Inc Peroxisome Proliferator Activated Receptor Delta Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 Mitobridge Inc Peroxisome Proliferator Activated Receptor Delta Business Region Distribution Analysis
8.7 Nippon Chemiphar Co Ltd
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Product A
8.7.2.2 Product B
8.7.3 Nippon Chemiphar Co Ltd Peroxisome Proliferator Activated Receptor Delta Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 Nippon Chemiphar Co Ltd Peroxisome Proliferator Activated Receptor Delta Business Region Distribution Analysis
8.8 Senju Pharmaceutical Co Ltd
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.2.1 Product A
8.8.2.2 Product B
8.8.3 Senju Pharmaceutical Co Ltd Peroxisome Proliferator Activated Receptor Delta Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 Senju Pharmaceutical Co Ltd Peroxisome Proliferator Activated Receptor Delta Business Region Distribution Analysis
8.9 T3D Therapeutics Inc
8.9.1 Company Profile
8.9.2 Product Picture and Specifications
8.9.2.1 Product A
8.9.2.2 Product B
8.9.3 T3D Therapeutics Inc Peroxisome Proliferator Activated Receptor Delta Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.9.4 T3D Therapeutics Inc Peroxisome Proliferator Activated Receptor Delta Business Region Distribution Analysis
9 Development Trend of Analysis of Peroxisome Proliferator Activated Receptor Delta Market
9.1 Global Peroxisome Proliferator Activated Receptor Delta Market Trend Analysis
9.1.1 Global 2018-2025 Peroxisome Proliferator Activated Receptor Delta Market Size (Volume and Value) Forecast
9.1.2 Global 2018-2025 Peroxisome Proliferator Activated Receptor Delta Sales Price Forecast
9.2 Peroxisome Proliferator Activated Receptor Delta Regional Market Trend
9.2.1 North America 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Forecast
9.2.2 Europe 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Forecast
9.2.3 China 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Forecast
9.2.4 Japan 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Forecast
9.2.5 Southeast Asia 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Forecast
9.2.6 India 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Forecast
9.3 Peroxisome Proliferator Activated Receptor Delta Market Trend (Product Type)
9.4 Peroxisome Proliferator Activated Receptor Delta Market Trend (Application)
10 Peroxisome Proliferator Activated Receptor Delta Marketing Type Analysis
10.1 Peroxisome Proliferator Activated Receptor Delta Regional Marketing Type Analysis
10.2 Peroxisome Proliferator Activated Receptor Delta International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Peroxisome Proliferator Activated Receptor Delta by Region
10.4 Peroxisome Proliferator Activated Receptor Delta Supply Chain Analysis
11 Consumers Analysis of Peroxisome Proliferator Activated Receptor Delta
11.1 Consumer 1 Analysis
11.2 Consumer 2 Analysis
11.3 Consumer 3 Analysis
11.4 Consumer 4 Analysis
12 Conclusion of the Global Peroxisome Proliferator Activated Receptor Delta Market Professional Survey Report
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Picture of Peroxisome Proliferator Activated Receptor Delta
Table Product Specifications of Peroxisome Proliferator Activated Receptor Delta
Table Classification of Peroxisome Proliferator Activated Receptor Delta
Figure Global Production Market Share of Peroxisome Proliferator Activated Receptor Delta by Type in
Figure MTB-2 Picture
Table Major Manufacturers of MTB-2
Figure HPP-593 Picture
Table Major Manufacturers of HPP-593
Figure CNX-013B2 Picture
Table Major Manufacturers of CNX-013B2
Figure CS-038 Picture
Table Major Manufacturers of CS-038
Figure MA-0204 Picture
Table Major Manufacturers of MA-0204
Figure Others Picture
Table Major Manufacturers of Others
Table Applications of Peroxisome Proliferator Activated Receptor Delta
Figure Global Consumption Volume Market Share of Peroxisome Proliferator Activated Receptor Delta by Application in
Figure Bone Disorders Examples
Table Major Consumers in Bone Disorders
Figure Colitis Examples
Table Major Consumers in Colitis
Figure Obesity Examples
Table Major Consumers in Obesity
Figure Osteoporosis Examples
Table Major Consumers in Osteoporosis
Figure Others Examples
Table Major Consumers in Others
Figure Market Share of Peroxisome Proliferator Activated Receptor Delta by Regions
Figure North America Peroxisome Proliferator Activated Receptor Delta Market Size (Million USD) (2013-2025)
Figure Europe Peroxisome Proliferator Activated Receptor Delta Market Size (Million USD) (2013-2025)
Figure China Peroxisome Proliferator Activated Receptor Delta Market Size (Million USD) (2013-2025)
Figure Japan Peroxisome Proliferator Activated Receptor Delta Market Size (Million USD) (2013-2025)
Figure Southeast Asia Peroxisome Proliferator Activated Receptor Delta Market Size (Million USD) (2013-2025)
Figure India Peroxisome Proliferator Activated Receptor Delta Market Size (Million USD) (2013-2025)
Table Peroxisome Proliferator Activated Receptor Delta Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Peroxisome Proliferator Activated Receptor Delta in
Figure Manufacturing Process Analysis of Peroxisome Proliferator Activated Receptor Delta
Figure Industry Chain Structure of Peroxisome Proliferator Activated Receptor Delta
Table Capacity and Commercial Production Date of Global Peroxisome Proliferator Activated Receptor Delta Major Manufacturers
Table Manufacturing Plants Distribution of Global Peroxisome Proliferator Activated Receptor Delta Major Manufacturers
Table R&D Status and Technology Source of Global Peroxisome Proliferator Activated Receptor Delta Major Manufacturers
Table Raw Materials Sources Analysis of Global Peroxisome Proliferator Activated Receptor Delta Major Manufacturers
Table Global Capacity, Sales , Price, Cost, Sales Revenue (M USD) and Gross Margin of Peroxisome Proliferator Activated Receptor Delta E
Figure Global E Peroxisome Proliferator Activated Receptor Delta Market Size (Volume) and Growth Rate
Figure Global E Peroxisome Proliferator Activated Receptor Delta Market Size (Value) and Growth Rate
Table E Global Peroxisome Proliferator Activated Receptor Delta Capacity and Growth Rate
Table Global Peroxisome Proliferator Activated Receptor Delta Capacity (K Pcs) List (Company Segment)
Table E Global Peroxisome Proliferator Activated Receptor Delta Sales (K Pcs) and Growth Rate
Table Global Peroxisome Proliferator Activated Receptor Delta Sales (K Pcs) List (Company Segment)
Table E Global Peroxisome Proliferator Activated Receptor Delta Sales Price (USD/Pcs)
Table Global Peroxisome Proliferator Activated Receptor Delta Sales Price (USD/Pcs) List (Company Segment)
Figure North America Capacity Overview
Table North America Supply, Import, Export and Consumption (K Pcs) of Peroxisome Proliferator Activated Receptor Delta E
Figure North America E Peroxisome Proliferator Activated Receptor Delta Sales Price (USD/Pcs)
Figure North America Peroxisome Proliferator Activated Receptor Delta Sales Market Share
Figure Europe Capacity Overview
Table Europe Supply, Import, Export and Consumption (K Pcs) of Peroxisome Proliferator Activated Receptor Delta E
Figure Europe E Peroxisome Proliferator Activated Receptor Delta Sales Price (USD/Pcs)
Figure Europe Peroxisome Proliferator Activated Receptor Delta Sales Market Share
Figure China Capacity Overview
Table China Supply, Import, Export and Consumption (K Pcs) of Peroxisome Proliferator Activated Receptor Delta E
Figure China E Peroxisome Proliferator Activated Receptor Delta Sales Price (USD/Pcs)
Figure China Peroxisome Proliferator Activated Receptor Delta Sales Market Share
Figure Japan Capacity Overview
Table Japan Supply, Import, Export and Consumption (K Pcs) of Peroxisome Proliferator Activated Receptor Delta E
Figure Japan E Peroxisome Proliferator Activated Receptor Delta Sales Price (USD/Pcs)
Figure Japan Peroxisome Proliferator Activated Receptor Delta Sales Market Share
Figure Southeast Asia Capacity Overview
Table Southeast Asia Supply, Import, Export and Consumption (K Pcs) of Peroxisome Proliferator Activated Receptor Delta E
Figure Southeast Asia E Peroxisome Proliferator Activated Receptor Delta Sales Price (USD/Pcs)
Figure Southeast Asia Peroxisome Proliferator Activated Receptor Delta Sales Market Share
Figure India Capacity Overview
Table India Supply, Import, Export and Consumption (K Pcs) of Peroxisome Proliferator Activated Receptor Delta E
Figure India E Peroxisome Proliferator Activated Receptor Delta Sales Price (USD/Pcs)
Figure India Peroxisome Proliferator Activated Receptor Delta Sales Market Share
Table Global E Peroxisome Proliferator Activated Receptor Delta Sales (K Pcs) by Type
Table Different Types Peroxisome Proliferator Activated Receptor Delta Product Interview Price
Table Global E Peroxisome Proliferator Activated Receptor Delta Sales (K Pcs) by Application
Table Different Application Peroxisome Proliferator Activated Receptor Delta Product Interview Price
Table Chipscreen Biosciences Ltd Information List
Table Product Overview
Table Chipscreen Biosciences Ltd Peroxisome Proliferator Activated Receptor Delta Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Chipscreen Biosciences Ltd Peroxisome Proliferator Activated Receptor Delta Business Region Distribution
Table Connexios Life Sciences Pvt Ltd Information List
Table Product Overview
Table Connexios Life Sciences Pvt Ltd Peroxisome Proliferator Activated Receptor Delta Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Connexios Life Sciences Pvt Ltd Peroxisome Proliferator Activated Receptor Delta Business Region Distribution
Table CymaBay Therapeutics Inc Information List
Table Product Overview
Table CymaBay Therapeutics Inc Peroxisome Proliferator Activated Receptor Delta Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure CymaBay Therapeutics Inc Peroxisome Proliferator Activated Receptor Delta Business Region Distribution
Table Genfit SA Information List
Table Product Overview
Table Genfit SA Peroxisome Proliferator Activated Receptor Delta Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Genfit SA Peroxisome Proliferator Activated Receptor Delta Business Region Distribution
Table Inventiva Information List
Table Product Overview
Table Inventiva Peroxisome Proliferator Activated Receptor Delta Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Inventiva Peroxisome Proliferator Activated Receptor Delta Business Region Distribution
Table Mitobridge Inc Information List
Table Product Overview
Table Mitobridge Inc Peroxisome Proliferator Activated Receptor Delta Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Mitobridge Inc Peroxisome Proliferator Activated Receptor Delta Business Region Distribution
Table Nippon Chemiphar Co Ltd Information List
Table Product Overview
Table Nippon Chemiphar Co Ltd Peroxisome Proliferator Activated Receptor Delta Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Nippon Chemiphar Co Ltd Peroxisome Proliferator Activated Receptor Delta Business Region Distribution
Table Senju Pharmaceutical Co Ltd Information List
Table Product Overview
Table Senju Pharmaceutical Co Ltd Peroxisome Proliferator Activated Receptor Delta Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Senju Pharmaceutical Co Ltd Peroxisome Proliferator Activated Receptor Delta Business Region Distribution
Table T3D Therapeutics Inc Information List
Table Product Overview
Table T3D Therapeutics Inc Peroxisome Proliferator Activated Receptor Delta Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure T3D Therapeutics Inc Peroxisome Proliferator Activated Receptor Delta Business Region Distribution
Figure Global 2018-2025 Peroxisome Proliferator Activated Receptor Delta Market Size (K Pcs) and Growth Rate Forecast
Figure Global 2018-2025 Peroxisome Proliferator Activated Receptor Delta Market Size (Million USD) and Growth Rate Forecast
Figure Global 2018-2025 Peroxisome Proliferator Activated Receptor Delta Sales Price (USD/Pcs) Forecast
Figure North America 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Volume (K Pcs) and Growth Rate Forecast
Figure China 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Europe 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Southeast Asia 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Japan 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Volume (K Pcs) and Growth Rate Forecast
Figure India 2018-2025 Peroxisome Proliferator Activated Receptor Delta Consumption Volume (K Pcs) and Growth Rate Forecast
Table Global Sales Volume (K Pcs) of Peroxisome Proliferator Activated Receptor Delta by Type 2018-2025
Table Global Consumption Volume (K Pcs) of Peroxisome Proliferator Activated Receptor Delta by Application 2018-2025
Table Traders or Distributors with Contact Information of Peroxisome Proliferator Activated Receptor Delta by Region
Market Segmentation Analysis
1. By Drug Type (Mechanism of Action):
-
Selective PPARδ Agonists: Designed to activate the receptor, promoting fatty acid oxidation, improving insulin sensitivity, and exerting anti-inflammatory effects. The dominant modality in development (e.g., seladelpar, elafibranor).
-
Dual/Tri-PPAR Agonists: Pan-agonists or dual agonists (e.g., PPARα/δ) aiming for synergistic benefits across multiple metabolic pathways.
-
PPARδ Modulators with Novel MoAs: Including selective PPARδ modulators (SPPARδMs) designed for tissue-specific effects and improved safety profiles.
2. By Therapeutic Application (Indication):
-
Metabolic & Liver Diseases (Primary Focus):
-
Metabolic Dysfunction-Associated Steatohepatitis (MASH): The largest potential market.
-
Primary Biliary Cholangitis (PBC): An established target with late-stage candidates.
-
Other Cholestatic & Fibrotic Liver Diseases.
-
-
Metabolic & Cardiovascular Disorders: Dyslipidemia, Type 2 Diabetes, and cardiovascular risk reduction.
-
Musculoskeletal & Rare Diseases: Ducheme Muscular Dystrophy (DMD), fibrodysplasia ossificans progressiva (FOP).
-
Inflammatory & Autoimmune Conditions: Ulcerative colitis, psoriasis.
3. By Development Phase:
-
Preclinical/Discovery
-
Phase I Clinical Trials (Safety & Pharmacology)
-
Phase II Clinical Trials (Proof-of-Concept; most active segment)
-
Phase III Clinical Trials & Regulatory Review (Future pivotal segment)
-
Post-Marketing (Commercial)
Regional Analysis
-
North America: The leading R&D and future commercial market, spearheaded by the U.S. High concentration of biotech innovation, favorable FDA regulatory pathways (Fast Track, Breakthrough Therapy), and significant venture capital funding.
-
Europe: A major hub for clinical research and development, with strong academic centers and pharmaceutical activity in France, the UK, and Germany. The EMA provides a key regulatory pathway.
-
Asia-Pacific: An increasingly important region for patient recruitment in global trials and a future high-growth market. Japan and China have active domestic developers (e.g., Chipscreen Biosciences) and large patient populations for metabolic diseases.
-
Rest of the World: Participation in multi-regional clinical trials is growing, but commercial markets will follow initial approvals in the U.S., EU, and Japan.
